Bremelanotide vs Melanotan II: What Melanocortin Selectivity Really Means

One Functional Group, Two Very Different Reputations

Here's the short version. Bremelanotide and melanotan II are the same cyclic peptide with a different group on the end, and the research literature describes both of them with the same unglamorous word — non-selective. If you're reading datasheets for either compound, both of which are supplied for research use only, the term worth interrogating is "selectivity." It's the most over-claimed property in melanocortin chemistry. And the question of bremelanotide vs melanotan II receptor selectivity has a more interesting answer than marketing copy or casual summaries usually allow.

This matters if you're sourcing either peptide as a reference chemical. A compound that engages four of five receptor subtypes behaves very differently in a cell assay than one that cleanly addresses a single target, and the controls you need follow directly from that.

Five Receptors, One Shared Message: The MC1R–MC5R Family

What this section tells you: before you can compare two melanocortin ligands, you need to know how many receptors they could be hitting. The answer is five, and four of them are in play.

The melanocortin receptors are a family of five class-A G-protein-coupled receptors, and research associates each one with a fairly distinct area. MC1R sits mostly on melanocytes and governs pigmentation; among the five subtypes it shows the highest affinity for α-MSH. MC2R is the odd one out. It lives in adrenal tissue, mediates adrenal steroidogenesis, and ACTH is its only known endogenous ligand — which is precisely why nothing in the melanotan class engages it at all.

MC3R and MC4R are the neural subtypes, expressed primarily in the central nervous system, where research models implicate MC3R in feed efficiency and MC4R in both food intake and energy expenditure. MC5R is the most broadly distributed of the set, with reported involvement spanning exocrine secretion, inflammation, immunomodulation, neuromuscular regeneration, and temperature control. Those are research associations, not outcomes a compound delivers — but they explain why a ligand that can't distinguish between subtypes creates interpretive problems.

What activation looks like downstream

MC1R is the clearest worked example. An agonist binds, and the Gαs protein separates while MC1R activates adenylyl cyclase, producing cAMP. That second messenger activates protein kinase A, which activates transcription factors that upregulate tyrosinase and dopachrome tautomerase — two enzymes in the melanin synthesis pathway. State that carefully, though: in cell-culture work, MC1R engagement is read out as enzyme expression and pigment production in the dish. The assay measures the cascade. Not a cosmetic result.

If the subtype map is new to you, our primer on the HFRW motif and the MC1R-MC5R family covers the whole family in more depth.

One Functional Group Apart: The Chemistry That Separates Them

What this section tells you: structurally, these are the same molecule with a different last atom-group — and that really is the whole story.

Both compounds are built on an identical cyclic heptapeptide: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]. The ring is a lactam bridge formed between the ε-amino group of lysine and the γ-carboxy group of aspartic acid, spanning positions 2 through 7 of the sequence. Inside that ring sits the His-D-Phe-Arg-Trp message segment, locked into a shape the open-chain parent peptide only samples now and then. We cover what that constraint buys in how the cyclic lactam reshapes an alpha-MSH analog.

The divergence happens at exactly one position. Melanotan II terminates in a primary amide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, molecular formula C₅₀H₆₉N₁₅O₉, 1024.20 g/mol, CAS 121062-08-6. Bremelanotide terminates in a free carboxylic acid: the same sequence ending in -OH, C₅₀H₆₈N₁₄O₁₀, 1025.18 g/mol, CAS 189691-06-3. One nitrogen swapped for one oxygen. Everything else is identical — the N-terminal acetyl cap, the norleucine substitution at position 4, the D-phenylalanine inversion, the lactam bridge.

The relationship is closer than "structural analogs," too. Bremelanotide is described in the literature as a deamidated derivative and likely metabolite of MT-II. Melanotan II is partly converted into bremelanotide, so the two are a chemical pair rather than independent discoveries.

Why one group can matter at all

A C-terminal amide and a C-terminal free acid aren't interchangeable. The acid carries a negative charge at physiological pH where the amide is neutral, which changes the local electrostatics any receptor contact surface sees. The hydrogen-bond donor and acceptor pattern at that end of the molecule changes too, and carboxypeptidases read a free C-terminus differently than a capped one. Our explainer on C-terminal amidation versus a free acid works through the general case; this pair is one of the cleanest illustrations of it.

Why the Shared Pharmacophore Makes Subtype Selectivity Hard

What this section tells you: neither compound is selective because selectivity was never really available on this scaffold.

Melanocortin agonism runs through a four-residue message. His-Phe-Arg-Trp (HFRW) is the pharmacophore — the minimally active sequence — and it's conserved across every pharmacologically addressable subtype. MC1R, MC3R, MC4R and MC5R all read the same four residues. Build a ligand around that motif and it's cross-reactive by default; the literature is explicit that the shared structure "creates inherent cross-reactivity among MCR subtypes."

That leaves a narrow engineering margin. Whatever selectivity a designer wants has to come from flanking residues and ring geometry rather than the message segment itself, because changing the message segment generally costs potency everywhere at once.

The linear comparison case

Afamelanotide, also called melanotan I, is useful here precisely because it's architecturally different. It's a 13-residue linear peptide — Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, or [Nle⁴, D-Phe⁷]-α-MSH. If cyclization were the thing that produced selectivity, the linear analog should be the promiscuous one. It isn't. Afamelanotide is also characterized as a non-selective agonist of melanocortin receptors except for MC2R.

That conclusion is worth carrying around. Linear versus cyclic changes stability, rigidity, and resistance to degradation — not subtype discrimination. We compare the two architectures head-to-head in linear versus cyclic alpha-MSH analogs.

Bremelanotide vs Melanotan II Receptor Selectivity: What the Numbers Say

What this section tells you: the published values describe a preference gradient, not a selectivity switch.

For melanotan II, reported affinities land at roughly 1.3 nM for MC3R and 1.1 nM for MC4R — essentially equipotent across the two neural subtypes. At MC1R, reported Ki values span a 0.2–6.4 nM range across assay systems. The same review literature calls melanotan II "superpotent" at MC4R relative to the endogenous ligands α-MSH and ACTH, a 10- to 100-fold affinity difference generally attributed to the conformational constraint the lactam ring imposes.

Bremelanotide's reported functional potencies are approximately EC₅₀ 0.095 nM at MC1R, 0.25 nM at MC4R, and 2.4 nM at MC3R. Read that as a roughly 10-fold functional preference for MC4R over MC3R. Real, but an order of magnitude isn't what most people mean by "selective" — that word usually implies a 100- to 1000-fold spread. Both compounds remain, in the reference sources' own language, non-selective agonists active at MC1R, MC3R, MC4R and MC5R with no meaningful MC2R activity.

Reading these numbers critically

Two cautions before any of these figures go in a table. First, affinity and functional potency are different measurements: a Ki from a competition binding experiment and an EC₅₀ from a cAMP accumulation readout answer different questions and aren't interchangeable. Our walkthrough of how radioligand binding assays measure Kd and Ki covers where the distinction bites. Second, values shift with cell line, radioligand choice, receptor expression level, and readout. Cross-paper comparison is hazardous. Treat any single published number as assay-specific rather than a property of the molecule.

The Structural Basis of Selectivity: Position 6.58 and a Calcium Ion

What this section tells you: structural biology has now identified which receptor residues decide subtype preference — and there are fewer of them than you'd hope.

Recent structural work on the human MC3R and MC5R put numbers on this. One position does a surprising amount of the work: residue 6.58 is isoleucine (I265) in MC3R, tyrosine (Y268) in MC4R, and methionine (M261) in MC5R. Mutating MC3R's isoleucine to methionine, tyrosine or tryptophan cut γ-MSH potency by 3-fold, 4-fold and 18-fold respectively. A single residue swap produces a measurable selectivity shift — which tells you both that the position matters and how little structural room a ligand designer has to work with.

Working against that is a conserved constraint. All melanocortin receptors share an EDD motif (E2.64, D3.25, D3.29) that coordinates a calcium ion required for peptide ligand binding. That coordination site is both essential and identical across subtypes, so no ligand can differentiate between receptors using that part of the pocket at all. The usable selectivity surface is smaller than the binding pocket.

What cyclization actually buys

The same structural work explains the appeal of the cyclic scaffold. In cyclic α-MSH analogs the ring mimics the native E5–K11 salt bridge of α-MSH, lowering the entropic cost of binding while preserving potency comparable to the natural ligand. Cyclization is a potency-and-stability strategy, then — not a selectivity strategy.

One more detail connects back. The structures show that subtype discrimination largely lives in C-terminal contacts: γ-MSH's C-terminus occupies an MC3R-specific complementary groove, while α-MSH's C-terminus "distances itself from the receptor with negligible contacts." That is precisely the region where melanotan II and bremelanotide differ — the structurally coherent explanation for why one functional group tilts their subtype profiles slightly without changing either compound's broad promiscuity.

Regulatory Divergence: An Approved Substance and an Unapproved Chemical

What this section tells you: chemically near-identical, legally not comparable at all.

Bremelanotide is the international nonproprietary name of an active pharmaceutical ingredient that the U.S. FDA approved in June 2019 as a first-in-class medication. Melanotan II has never been approved in any jurisdiction. Unregulated products are not legal to be sold for human usage anywhere, and health agencies worldwide have issued warnings since 2007 citing safety and product-purity concerns.

That asymmetry has a practical consequence for anyone sourcing reference material. Research-grade bremelanotide is not equivalent to the approved pharmaceutical product carrying the same chemical name. It's a laboratory reference chemical: not manufactured to pharmacopeial specifications, not subject to the identity, purity, and quality assurances that attach to an approved drug product, and intended for in-vitro research only. Verifying identity and purity on receipt stays the researcher's responsibility.

Frequently Asked Questions

Is bremelanotide more selective than melanotan II?

Not in the strict pharmacological sense. Both compounds are described in the literature as non-selective melanocortin agonists with measurable activity at MC1R, MC3R, MC4R and MC5R, and neither engages MC2R. What the published numbers show is a difference in degree rather than kind: bremelanotide's reported functional potencies skew toward MC4R over MC3R by roughly an order of magnitude, while melanotan II is close to equipotent at those two subtypes. Calling bremelanotide MC4R-preferring is defensible; calling it MC4R-selective overstates what the data support.

What is the actual chemical difference between bremelanotide and melanotan II?

One functional group at the C-terminus. Melanotan II is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, terminating in a primary amide. Bremelanotide is the same cyclic heptapeptide terminating in a free carboxylic acid, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Everything else — the N-terminal acetyl group, the norleucine substitution, the D-phenylalanine inversion, the Lys-Asp lactam bridge — is identical. The molecular formulas differ by a single nitrogen-for-oxygen swap: C₅₀H₆₉N₁₅O₉ versus C₅₀H₆₈N₁₄O₁₀.

Why is subtype-selective melanocortin ligand design so difficult?

Because all four pharmacologically addressable receptors read the same four-residue message. The His-Phe-Arg-Trp (HFRW) tetrapeptide is the minimal active sequence for melanocortin agonism, and it is conserved across MC1R, MC3R, MC4R and MC5R. A ligand built around that motif is therefore cross-reactive by default. Selectivity has to come from somewhere other than the pharmacophore — usually from flanking residues that contact subtype-specific regions of the binding pocket, which is a much narrower engineering margin than designers get with most receptor families.

Is research-grade bremelanotide the same thing as the FDA-approved product with that name?

No. Bremelanotide is the international nonproprietary name of an active pharmaceutical ingredient that the U.S. FDA approved in June 2019 under a brand name, in a specific formulation, manufactured to pharmaceutical specifications. Research-grade material sold under the same chemical name is not that product. It is a reference chemical intended for laboratory work only, is not manufactured to pharmacopeial standards, and carries none of the identity, purity, or quality assurances that attach to an approved drug product.

The Bottom Line

The bremelanotide and melanotan II pair is a case study in how little selectivity a shared pharmacophore permits. One functional group separates them, and both stay broadly active across four of the five melanocortin subtypes. The reported numbers support calling bremelanotide MC4R-preferring — roughly a 10-fold tilt toward MC4R over MC3R — and nothing stronger. "Selective" is the wrong word for either compound.

What is changing is the structural picture. Cryo-EM work on MC3R and MC5R is now exposing the specific residues a genuinely subtype-selective ligand would have to exploit — where the next generation of melanocortin chemistry is pointed. For groundwork, start with the melanocortin receptor family and cyclic versus linear peptide architecture.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.